In the context of chimeric antigen receptor (CAR)-T cell therapy, the proinflammatory nature of CH, including elevated levels of circulating IL-1 and IL-6 classically associated with TET2 variants, may increase the risk of cytokine release syndrome (CRS) and other immune toxicities (Singh and Balasubramanian, 2024). The gene discussed is TET2; the disease is cyclic hematopoiesis.